An interventional study of WEB in Wide Neck Bifurcation Intracranial Aneurysms, sponsored by Microvention-Terumo, Inc.. Recruiting at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Microvention-Terumo, Inc. (part of Terumo Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Aneurysm by Terumo Corporation — 3 open to participants now, 6 under way, none of them phase 3. Aneurysm · Terumo Corporation.
Among the 15 studies in Aneurysm by Terumo Corporation, this one is one of 2 that started in 2022, is one of 6 with no phase, and was the 13th registered.
381 studies on the registry are indexed under Aneurysm; 78 are open to participants now.
Browse Aneurysm studies →3 of the 15 studies in Aneurysm by Terumo Corporation are open now, in 8 countries. Recruiting first, the newest first:
Vascutek Ltd. · Sites in United States, Austria, Germany and 2 more countries
Ages 18+
Vascutek Ltd. · Sites in United States, Belgium, France and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 67 Aneurysm studies recruiting now, 42 (63%) set no upper age limit and 7 (10%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 200 is above the median of 46 across 235 interventional studies indexed under Aneurysm.
Median enrollment 150 across the 7 interventional studies, 182 across the 7 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Microvention-Terumo, Inc., one of the names counted as Terumo Corporation. Under that name alone:
Microvention-Terumo, Inc. is the lead sponsor of 32 studies on the registry; 7 are open to participants now.
2 of the studies in Aneurysm by Terumo Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04839705Microvention-Terumo, Inc.Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device | 2027-05-08 |
| NCT07078383Vascutek Ltd.A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Aneurysm by Terumo Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation. The primary effectiveness outcome of the study is adequate intracranial aneurysm occlusion on the 1 year angiogram as adjudicated by a core laboratory.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
WEB Aneurysm Embolization Device The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
Device: WEB
Device: WEB The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. Other Names: • WEB Aneurysm Embolization Device
Key Effectiveness Outcome
Proportion of subjects with adequate aneurysm occlusion at one year after treatment.
Time frame: 12 Months
Key Safety Outcome
Proportion of subjects with death of any nonaccidental cause or any major stroke\* within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment
Time frame: 12 Months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for May 2027, 56 months after the start.
Of 83 interventional studies with no phase under Aneurysm, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 134. This study's planned 56 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion May 2026 → May 2027 and completion May 2030 → May 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.